|
48 |
Unraveling the contribution of complement in the initial days post lung transplantation Inge Van de Walle1, Karen De winter1, Laura Bracke1, Tim Delahaye1, Rene Novysedlak2, Jan Van Slambrouck2, Annalisa Barbarossa2, Xin Jin2, Pheline Kortleven2, Janne Kaes2, Hanne Beeckmans2, Sandra Claes Claes3, Dominique Schols3, Ariella Van de Sompel1, Erik Hack1, Saskia Bos2, Robin Vos2, Bart M Vanaudenaerde2, and Laurens J Ceulemans2
|
|
49 |
Structural insights into IgM and complement activationJunyu Xiao
|
|
50 |
Serum complement internalization is needed for UV-mediated nuclear bubbling cell deathNan-Shan Chang, and Cheng-Chang Tsai
|
|
51 |
Therapeutic Potential of the C3aR Antagonist JR14a in Heart Failure With Preserved Ejection Fraction (HFpEF)Elias Rawish1, Carolin Gragoll1, Michael Schneider1, Timo Rusack1, Jörg Köhl2, and Ingo Eitel1
|
|
52 |
Astrocyte-Derived Complement C3 Drives Metabolic Syndrome via C3a Receptor Activation in Hypothalamic Appetite-Regulating NeuronsCarolin Gragoll1, Elias Rawish1, Michael Schneider1, Timo Rusack1, Joerg Koehl2, and Ingo Eitel1
|
|
53 |
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry Burt T. Richards1, Bert R.J. Veuskens2, Chris M. Pappas1, Jin Liu1, Robert A. Anstadt1, Marc Toso1, Jennifer Mohler1, Jill Hageman1, Brandi L. Williams1, Moussa A. Zouache1, Richard B. Pouw2, and Gregory S. Hageman1
|
|
54 |
Combined complement C3 and CD14 inhibition reduce live Escherichia coli-induced inflammation, but not platelet activation in the presence and absence of antibioticsOle- L. Brekke1,2, Ingrid S. Joakimsen1, Bård O. Karlsen1, Åse E. Emblem1, Kristin Pettersen1, Renathe H. Grønli1, and Tom E. Mollnes1,3
|
|
55 |
Contribution of complement activating anti-PLA2R1 autoantibodies in membranous nephropathyMarco Catalano1, Sara Montagner2, Elisabetta Traggiai2, and Elion Hoxha4
|
|
56 |
Cell-intrinsic complement in endotheliumMarina De Castro Deus, Idris Boudhabhay, and Lubka Roumenina
|
|
57 |
Immunostimulatory tRNA-derived RNAs in the circulation of patients with tuberculosis infectionJustin T Gumas, Takuya Kawamura, Megumi Shigematsu, and Yohei Kirino
|
|
58 |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activationAnna Świerzko1, Krzysztof Mikołajczyk2, Anna Maciejewska3, Dariusz Martynowski4, Łukasz Sobała2, Gabriela Gajek1, Paweł Link-Lenczowski5, Marcin Czerwiński2, Jolanta Łukasiewicz3, and Maciej Cedzyński1
|
|
59 |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)Cedric Battaglino1, Iryna Bodnaruk3, Katarzyna Kasperkiewicz3, Paula Czyszczoń4, Beata Filip-Psurska5, Kamil Malik3, Mikael Skurnik6, Maciej Cedzyński1, Dariusz Jarych1, Mariusz Gadzinowski, Jolanta Łukasiewicz4, and Anna Świerzko1
|
|
60 |
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).Rossella Piras1, Zahra Imanifard1, Anna Schubart2, Elena Bresin1, Ariela Benigni1, Giuseppe Remuzzi1, Marina Noris1, and Roberta Donadelli1
|
|
61 |
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)Zahra Imanifard1, Francesca Penati1, Sofia Padoa1, Paulina Dabrowska-Schlepp2, Elena Bresin1, Ariela Benigni1, Giuseppe Remuzzi1, Marina Noris1, and Roberta Donadelli1
|
|
62 |
Design and Evaluation of Glycomimetics as Ficolin-1 AntagonistsSaid Rabbani, Oliver Schwardt, Martin Smiesko, and Daniel Ricklin
|
|
63 |
A novel multiplex functional assay can be utilized to elucidate the mechanisms of the complement system.Lucia Iuzzolino1, Christina Hanack1, Pascal Deschatelets2, and Martin Kolev2
|
|
64 |
A Novel Tool for Complement Activation Profiling in AAV Gene TherapySamuel J Butler2, Klaudia Kulak1, Viktoria Kozma1, Cecilia Klint1, Camilla Nilsson1, Selvi Celik1, and Jordi Rodo2
|
|
65 |
Asymmetric dimethylarginine: a biomarker bridging coronary heart disease and metabolical associated steatotic liver diseaseMunisakhon Majidovna Makhkamova
|
|
66 |
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplanLuca Antonucci1,2, Antonio Gargiulo1, Andrea Cappoli1, Carolina Giannini1, Isabella Guzzo1, Marina Noris3, Francesco Emma1, and Marina Vivarelli4
|
|
67 |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGNCarla M Nester1, Andrew S Bomback2, Gema Ariceta3, Yahsou Delmas4, Bradley P Dixon5, Daniel P Gale6, Larry A Greenbaum7, Seung Hyeok Han8, Nicole Isbel9, Christoph Licht10, Antonio Mastrangelo11, Masashi Mizuno12, Maria Izabel Neves de Holanda13, Matthew C Pickering14, Giuseppe Remuzzi15, Nicole Van De Kar16, Marina Vivarelli17, Patrick D Walker18, Dean Wallace19, Daniel Zecher20, Li Li21, Zhongshen Wang21, Luis López Lázaro22, Johan Szamosi22, and Fadi Fakhouri23
|
|
68 |
Granzyme K Activates the Entire Complement CascadeCarlos A Donado1, Erin Theisen1,2, A. Helena Jonsson3, and Michael B Brenner1,2
|
